• Lung Cancer · Dec 2001

    Clinical Trial

    Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study.

    • M R Valerio, A Russo, M A Latteri, G Modica, G Gulotta, M G Armata, E Bajardi, G Cicero, G Pantuso, N Grassi, G Agosta, and N Gebbia.
    • Servizio di Chemioterapia, Policlinico Universitario P.Giaccone, Via del Vespro, 127-90127, Palermo, Italy.
    • Lung Cancer. 2001 Dec 1; 34 Suppl 4: S31-5.

    AbstractTo evaluate the efficacy and toxicity of weekly docetaxel (D) as II line treatment in non-small cell lung cancer (NSCLC), in November 1999, we started a phase II study on advanced (stages IIIB-IV) NSCLC patients pre-treated with at least one platinum-based chemotherapy regimen with or without radiotherapy. The schedule consisted of D 40 mg/m(2), weekly for 6 weeks, followed by a rest period of 2 weeks, for three cycles or until progression. Eligibility criteria were: histopathologic diagnosis of NSCLC; age

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…